Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-06
2006-06-06
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S653000
Reexamination Certificate
active
07056936
ABSTRACT:
The invention relates to the combined administration of PDE inhibitors and β2adrenoceptor agonists for the treatment of respiratory tract disorders.
REFERENCES:
patent: 3840537 (1974-10-01), Garside et al.
patent: 3941785 (1976-03-01), Clarke et al.
patent: 4400506 (1983-08-01), Lal et al.
patent: 4992474 (1991-02-01), Skidmore et al.
patent: 5602110 (1997-02-01), Drumm et al.
patent: 5712298 (1998-01-01), Amschler
patent: 5795564 (1998-08-01), Aberg et al.
patent: 5804588 (1998-09-01), Dyke et al.
patent: 6288118 (2001-09-01), Nieman et al.
patent: 2390164 (1998-12-01), None
patent: 00/67741 (2000-11-01), None
Torphy, T.J., et al. “Stimulation ofBetaAdrenoceptors in a Human Monocyte Cell Line (U937) Up-Regulates Cyclic AMP-Specific Phosphodiesterase Activity”,Journal of Pharmacology and Experimental Therapeutics, vol. 263, pp. 1195-1205, (1992).
Maesen, B.L.P., et al., “Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease”,Eur Respir J, vol. 13, pp. 1103-1108, (1999).
Campillo, N., et al., “Novel bronchodilators in the treatment of asthma and COPD”,Expert Opin. Ther. Patents, vol. 12, No. 1, pp. 53-63, (2001).
Tanizawa, M., et al., “Phosphodiesterase IV Inhibitors Synergistically Potentiate Relaxation Induced by Forskolin in Guinea-Pig Trachea”,Clinical and Experimental Pharmacology and Physiology, vol. 25, pp. 114-119, (1998).
Au, B-T, et al., “Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol”British Journal of Pharmacology, vol. 123, pp. 1260-1266, (1998).
Giembycz, M.A., “Phosphodiesterase 4 and tolerance to β2-adrenoceptor agonists in asthma”,TiPS, vol. 17, pp. 331-336, (1996).
Krasnowska, M., et al., “Treatment of Bronchial Asthma with Low Doses of Papaverine Combined with BETA Stimulators”,PNEUM. POL., No. 1-2, pp. 21-24, (1982).
Turner, N.C., et al., “Relaxation of guinea-pig trachea by cyclic AMP phosphodiesterase inhibitors and their enhancement by sodium nitroprusside”,Br. J. Pharmacol., vol. 111, pp. 1047-1052, (1994).
Rasmussen, J.B., et al., “Additive Bronchodilator Effects of Terbutaline and Enprofylline in Asthma”,Eur J Clin Pharmacol, vol. 32, pp. 23-26, (1987).
Persson, C.G.A., et al., “Tracheal Relaxation from Combinations of Xanthines and of a β2-Receptor Agonist and Xanthines”,Lung, vol. 164, pp. 33-40, (1986).
Kilian Ulrich
Schudt Christian
Altana Pharma AG
Goldberg Joshua B.
McGee Sheldon M.
Nath & Associates PLLC
Spivack Phyllis G.
LandOfFree
Synergistic combination does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synergistic combination, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synergistic combination will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3708390